MarketCap
Facebook
X
Telegram
Aileron Therapeutics Net Income | ALRN
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Aileron Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -49.9 M | -62.9 M | -15.7 M | -27.3 M | -26.2 M | -27.3 M | -29.4 M | -31.5 M | -22.6 M | -18.1 M | -12.9 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -12.9 M | -62.9 M | -29.4 M |
Quarterly Net Income Aileron Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.84 M | -5.58 M | -6.82 M | -5.5 M | - | -5.85 M | -8.94 M | -7.11 M | - | -1.83 M | -1.79 M | -4.78 M | - | -6.37 M | -7.99 M | -8.42 M | - | -6.7 M | -5.69 M | -6.98 M | -4.93 M | -5.02 M | -4.39 M | -6.75 M | -7.24 M | -7.75 M | -7.17 M | -7.21 M | -7.03 M | -7.43 M | -9.49 M | -7.59 M | -6.86 M | -6.26 M | -4.92 M | -4.56 M | -4.44 M | -4.22 M | -5.53 M | -3.92 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.79 M | -9.49 M | -6.08 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
14.5 M | - | -6.63 % | $ 13.9 M |  USA |
 |
FSD Pharma
HUGE
|
-27 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Qilian International Holding Group Limited
QLI
|
-19.9 M | - | -6.08 % | $ 184 M |  China |
 |
Synthetic Biologics
SYN
|
-23.7 M | - | 1.32 % | $ 16.2 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
27.3 M | - | - | $ 2.02 B | USA |
 |
Assembly Biosciences
ASMB
|
-6.12 M | $ 34.38 | 2.54 % | $ 385 M | USA |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M | China |
 |
Corner Growth Acquisition Corp.
COOL
|
-322 K | - | -0.89 % | $ 114 M | USA |
 |
AgeX Therapeutics
AGE
|
-19.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Axsome Therapeutics
AXSM
|
-183 M | $ 207.77 | 0.53 % | $ 10.3 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Aytu BioScience
AYTU
|
-13.6 M | $ 2.37 | 3.95 % | $ 14.9 M | USA |
 |
Happiness Biotech Group Limited
HAPP
|
-12.7 M | - | 1.35 % | $ 17.8 M | China |
 |
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-17 M | - | -13.47 % | $ 169 M | France |
 |
BioLineRx Ltd.
BLRX
|
-2.03 M | $ 2.81 | 1.81 % | $ 6.93 B |  Israel |
 |
CureVac N.V.
CVAC
|
162 M | - | - | $ 867 M |  Germany |
 |
BioMarin Pharmaceutical
BMRN
|
349 M | $ 66.7 | 0.14 % | $ 12.8 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-106 M | - | - | $ 269 M | USA |
 |
NanoViricides
NNVC
|
-9.47 M | $ 1.33 | 1.53 % | $ 20.1 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-40 M | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
-8.5 M | - | - | $ 4.9 B |  Britain |
 |
Завод ДИОД
DIOD
|
37.2 M | - | - | - |  Russia |
|
Galera Therapeutics
GRTX
|
149 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.38 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Hepion Pharmaceuticals
HEPA
|
-8.28 M | - | -18.79 % | $ 39.3 K | USA |
 |
ARCA biopharma
ABIO
|
-105 M | - | 1052.0 % | $ 415 M | USA |
 |
MorphoSys AG
MOR
|
-190 M | - | 2.43 % | $ 254 M | Germany |
 |
BioXcel Therapeutics
BTAI
|
-69.9 M | $ 0.8 | 0.66 % | $ 9.77 M | USA |
 |
Burford Capital Limited
BUR
|
62.6 M | $ 4.31 | 1.29 % | $ 945 M | Britain |
 |
Affimed N.V.
AFMD
|
-106 M | - | -34.95 % | $ 21.5 M | Germany |
 |
Arcutis Biotherapeutics
ARQT
|
-16.1 M | $ 25.08 | 1.12 % | $ 3.19 B | USA |
 |
Atara Biotherapeutics
ATRA
|
32.7 M | $ 9.7 | 3.41 % | $ 122 M | USA |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
-102 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
-40.9 M | - | - | $ 12.5 M |  Belgium |
 |
BeyondSpring
BYSI
|
-1.01 M | $ 0.72 | 0.81 % | $ 29.6 M | USA |
 |
Adial Pharmaceuticals
ADIL
|
-7.98 M | $ 6.22 | 5.34 % | $ 4.16 M | USA |
 |
Generation Bio Co.
GBIO
|
-132 M | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
Anika Therapeutics
ANIK
|
-10.9 M | $ 21.78 | 2.06 % | $ 312 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
3 M | - | -4.36 % | $ 27 M | USA |
 |
Gracell Biotechnologies
GRCL
|
-608 M | - | - | $ 3.37 B | China |
 |
GlycoMimetics
GLYC
|
154 K | - | 9357.83 % | $ 1.01 B | USA |
 |
AnaptysBio
ANAB
|
-13.2 M | $ 57.74 | 1.85 % | $ 1.66 B | USA |
 |
Compugen Ltd.
CGEN
|
35.3 M | $ 2.62 | 0.19 % | $ 245 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-10.4 M | - | 5.93 % | $ 314 M | Canada |
 |
AVROBIO
AVRO
|
-74.2 B | - | 1083.1 % | $ 745 M | USA |